Category | GROUP 1: Cohort 1 (RO6870810 0.30 mg/kg) + Atezo | GROUP 1: Cohort 2 (RO6870810 0.45 mg/kg) + Atezo | GROUP 1: Cohort 3 (RO6870810 0.65 mg/kg) + Atezo | GROUP 2: Cohort 1| (run-in with RO6870810 0.30 mg/kg) THEN (RO6870810 0.30 mg/kg) + Atezo | GROUP 2: Cohort 2| (run-in with RO6870810 0.45 mg/kg) THEN (RO6870810 0.45 mg/kg) + Atezo | GROUP 3: Expansion Group TNBC | GROUP 4: Expansion Group OC |
---|---|---|---|---|---|---|---|
N | 4 | 7 | 6 | 4 | 6 | 3 | 6 |
PR | 1 (25%) | 1 (14.3%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
SD | 1 (25%) | 2 (28.6%) | 4 (66.7%) | 1 (25%) | 5 (83.3%) | 2 (66.7%) | 0 (0%) |
PD | 2 (50%) | 3 (42.9%) | 1 (16.7%) | 3 (75%) | 1 (16.7%) | 0 (0%) | 4 (66.7%) |
Missing | 0 (0%) | 1 (14.3%) | 1 (16.7%) | 0 (0%) | 0 (0%) | 1 (33.3%) | 2 (33.3%) |
Responder | 1 (25%) | 1 (14.3%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
Non-Responder | 3 (75%) | 6 (85.7%) | 6 (100%) | 4 (100%) | 6 (100%) | 3 (100%) | 6 (100%) |